ABSTRACT A congenital hypodysfibrinogenemia, fibrinogen Baltimore H, was found in a young asymptomatic Caucasian female. Prothrombin, partial thromboplastin, and euglobulin lysis times were normal, as were platelet function and coagulation factor assays. Subnormal plasma fibrinogen levels were found using chronometric, rate-independent, and immunologic assay methods. Kinetic analysis of fibrinopeptide release revealed a delay in the thrombin-catalyzed release of fibrinopeptide B from the abnormal protein. Proteolysis of fibrinopeptide A by thrombin or -Arvin, fibrin monomer polymerization, and fibrin polymer ligation occurred at normal rates. -Catabolism of radiolabeled autologous and homologous fibrinogen was also normal, but the fibrinogen synthetic rate was -less than half the normal value. Tyler (18). Factors VII and X were measured as follows: citrated patient plasma was diluted 1:10 with 0.9% NaCl, and 0.15 ml of this solution was combined with an equal amount of factor-deficient plasma. A onestage PT was then performed as described above. The results were compared with a standard curve generated in the same manner using pooled normal plasma.
Congenital dysfibrinogenemia is an inherited disorder of fibrinogen synthesis in which a-presumed structural abnormality results in altered coagulation characteristics of the protein. The clinical manifestations of the disease vary from hemorrhagic diathesis to thrombosis. The characteristic clinical laboratory finding in dysfibrinogenemia is an apparently low plasma fibrinogen concentration using an assay dependent on the rate of clot formation. This value usually falls within normal limits when a rate-independent method is used.
In lieu of information concerning the precise location -of a molecular defect, dysfibrinogens have been classified on the basis of their functional characteristics (1) (2) (3) . The etiology of dysfibrinogenemia has been related to alterations in the primary structure of the protein. Blomback et al. (4) were the first to identify such a defect, and more recently four different abnormal proteins have been similarly characterized (5) (6) (7) (8) .
In this report a congenital hypodysfibrinogenemia, fibrinogen Baltimore II, is described. To the best of our knowledge, this represents the seventh documented case of dysfibrinogenemia occurring coincidentally with hypodysfibrinogenemia and the only one in which subnormal plasma fibrinogen concentrations have occurred coincidentally with delayed release of fibrinopeptide B.
METHODS
Blood. Blood was obtained by venipuncture and plasmapheresis performed with citrate/phosphate/dextrose (Fen-wall Laboratories, Deerfield, IL) as anticoagulant. Patient plasma used for clinical studies was prepared by diluting 9 vol of whole blood with 1 vol of 3.'8% trisodium citrate dihydrate.
Fibrinogen. Fibrinogen was purified from citrate/phosphate/dextrose plasma by three glycine precipitation steps (9) at room-temperature. Fibrinogen isolated in this way from normal or abnormal plasma was >98% coagulable when assayed by the method of Laki (10) and appeared similarly homogeneous when analyzed by NaDodSO4/polyacrylamide gel electrophoresis (11) under reducing conditions. Commercial normal human fibrinogen (Kabi, grade L, Stockholm, Sweden) was further purified as above by glycine precipitation. This preparation was used as "control" fibrinogen unless otherwise noted.
Thrombin Tyler (18) . Factors VII and X were measured as follows: citrated patient plasma was diluted 1:10 with 0.9% NaCl, and 0.15 ml of this solution was combined with an equal amount of factor-deficient plasma. A onestage PT was then performed as described above. The results were compared with a standard curve generated in the same manner using pooled normal plasma.
Platelet aggregometry was performed on a platelet aggregation profiler (BioData, Horsham, PA) at 37C with plateletrich plasma (=300,000 platelets per mm3) and the following as aggregating agents in a final volume of 0.5 ml: [2] [3] [4] [5] [6] [7] [8] [9] [10] '"I-Labeled normal human fibrinogen (for injection) was obtained from Amersham (IBRIN; lot no. 0179) and when administered had a specific radioactivity of 75.3 pCi/mg. This material was 92% coagulable by thrombin and 95% of the radioactivity was precipitated by 10% trichloroacetic acid. After providing informed, witnessed written and verbal consent, the affected father of the proposita was injected with a sterile solution containing 0.6 ml (45.2 uCi, 0.6 mg) of '"I-labeled normal fibrinogen and 2.6 ml (27.4 ,Ci, 7.8 mg) of '31I-labeled fibrinogen Baltimore II. Five-milliliter blood samples were collected at the indicated times over a period of 7 days, and 1-2.5 ml of plasma derived therefrom was assayed for radioactivity on a Beckman (Gamma 8000) gamma counter. The radioactivity in each of seven 24-hr urine samples collected during the same period was determined. Beginning 3 days prior to the study and for 17 days thereafter, the patient received daily 200 mg of potassium iodide orally.
Rates of fibrinogen synthesis and catabolism were calculated from plots of plasma radioactivity vs. time, assuming a twocompartment model (22, 23) . Kinetic constants were obtained by fitting a biexponential equation (24) to the data with the aid of a computer program by using the Newton-Raphson method for nonlinear parameter estimation (25) . A correction for nonprotein-bound iodide was made (23) . The fractional catabolic rate was determined from urinary excretion data by dividing the total cpm in urine collected during a 24-hr period by the total plasma radioactivity at the midpoint of the collection pe- Table 3 . Plasma volume (3.04 liter; 37.2 ml/kg) was estimated by dividing the total protein-bound radioactivity injected by the radioactivity concentration in the first blood sample. RESULTS Clinical Laboratory Findings. This 25-year-old Caucasian female has been in excellent health all of her life. At age 18 yr, symptomatic impacted wisdom teeth necessitated dental extraction, and, because of a history of some post-tonsillectomy bleeding, routine coagulation studies were performed. PT, activated PTT, euglobulin lysis time, factor assays, and platelet function were all within normal limits (Table 1) . However, as is typical of dysfibrinogenemia, plasma fibrinogen concentrations appeared to be low when estimated by two methods dependent on the rate of coagulation (Table 2) . However, when a method that did not depend on the rate of fibrinogen coagulation was used, the estimate of plasma fibrinogen concentration more than doubled but remained subnormal ( Fig. 1 and Table 2 ). These results were confirmed by serial dilution experiments using the Ouchterlony double-immunodiffusion technique (30) (data not shown).
Chronometric fibrinogen determinations (Fig. 1) on the patient's 11 relatives were normal except for her father and only son, whose symptoms and clinical laboratory findings closely resembled those reported here. The pattern of inheritance of the disorder (Fig. 1) is consistent with an autosomal dominant mode of transmission.
Coagulation Studies. The coagulability of the abnormal plasma was studied under a variety of conditions (Fig. 2) . For each of these experiments the fibrinogen concentration in the control plasma was diluted to match that of the proposita (estimated at 82 mg/dl), but, because the pH and ionic strength of the reaction mixtures differ, coagulation times between experiments are not comparable. Thrombin added in increasing amounts to normal and abnormal plasma reduces the coagulation time for both but restores the latter to near normal levels ( Fig. 2A) , a finding consistent with a proteolytic phase coagulation defect. Addition of calcium to normal or abnormal plasma is also effective in reducing the coagulation time (Fig. 2B) . However, the net reduction in each case (normal vs. abnormal) is to :60% of the coagulation time in the absence of calcium, thus indicating no difference in the net effect of calcium on coagulation behavior. The relationship between coagulation time and pH over a range of 5.7-8.5 was similar for the abnormal and control plasma (Fig. 2C) . The addition of abnormal plasma to normal plasma did not affect the coagulation time of the latter (Fig.  2D) , which indicates that the abnormal plasma does not contain a circulating anticoagulant.
Determination of the Functional Abnormality. When the kinetics of individual fibrinopeptide release were examined, fibrinopeptide A was released at a rate and to an extent similar to that of the control (Fig. 3A) . The release of fibrinopeptide B was delayed, although the total amount of peptide was -80% of normal at later time points (Fig. 3B) . For other experiments (not shown) in which higher concentrations of thrombin were To determine the effect of thrombin concentration on coagulation time (A) 0.1 ml of bovine thrombin [in 25 mM sodium diethyl barbiturate (pH 7.5) containing 125 mM NaCl] was added to 0.1 ml of citrated plasma. The effect of calcium on thrombin-catalyzed clotting time (B) was studied by combining 0.2 ml of citrated plasma with 0.1 ml of a 14.5 mM NaCl solution containing 15 u ofbovine thrombin per ml and 5-60 mM CaCl2. The effect of pH on coagulation time (C) was determined by mixing one part citrated plasma with two parts Michaelis buffer (pH 5.7), after which each solution was diluted to the same final volume with water to ensure equivalent fibrinogen concentrations. Coagulation was initiated by adding 0.1 ml of bovine thrombin (25 u/ml) to 0.2 ml of buffered plasma solution. e, Control in A-C; o, Baltimore II in A-C. The effect of mixing normal and abnormal plasma on thrombin-catalyzed clotting time (D) was studied by combining 0.2 ml ofnormal plasma [previously diluted with either patient plasma (0) or normal saline (s)] with 0.2 ml of bovine thrombin (10 u/mi). For each of the above reactions, clot formation was monitored visually at 370C, and each point represents the mean of triplicate determinations. used, the total amount of fibrinopeptide B released was identical to that of the control. The delay is completely abolished at a final thrombin concentration of >3 u/ml and is substantially prolonged at enzyme concentrations of <0.1 u/ml.
The observation of a prolonged Arvin clotting time (Table 2) indicates that fibrinopeptide A is released more slowly than normal in plasma. We attempted to confirm this using HPLC to monitor fibrinopeptide A release from isolated fibrinogen but found the rate and extent of peptide generation to be normal (data not shown). As expected, no fibrinopeptide B was detected under these conditions.
No abnormalities regarding the initial rates of fibrin monomer polymerization were found (Fig. 4) , and the plasma clot Time, sec  FIG. 4 . Polymerization of fibrin monomers. Purified normal and abnormal fibrinogen (3.0 ml of a solution at 2.5 mg/ml) was combined with human thrombin (5 u in 50 p1L) and the mixture was allowed to clot for 30-45 min at 250C. The clot was removed with a glass rod, washed three times by immersion in 7 ml of distilled water for 10 min, and dissolved in 1 ml of 20 mM sodium acetate buffer (pH 4.2). The protein concentration was determined by absorbance at 280 nm (31) and the Lowry method (32). Polymerization was initiated by mixing 0.5 ml of a fibrin solution at 1 mg/ml (in sodium acetate buffer) with an equal volume of 80 mM Na2HPO4, to produce a pH 7.4 solution with an ionic strength of 0.10. IEF of isolated fibrinogen (Fig. 5 ) revealed the typical pattern of 13-15 protein bands (33) . No difference between the normal and abnormal fibrinogens was found. Immunoelectrophoresis (3% agar, pH 8.6) of fibrinogen Baltimore II also failed to reveal any differences from normal (data not shown).
Metabolic Studies. The plasma clearance curves for radiolabeled autologous and homologous fibrinogen were virtually identical (Fig. 6) . The corresponding half-lives, intravascular distributions, and fractional catabolic rates were similar and within normal limits (Table 3) . However, the rate of fibrinogen synthesis was well below normal for the autologous fibrinogen Cable 3). Thus, the subnormal fibrinogen concentration results from a decreased rate of fibrinogen synthesis or secretion.
DISCUSSION
In accordance with the nomenclature suggested by Beck et it is apparent in the present case that no serious bleeding, thrombotic episodes, or abnormal wound healing could be attributed to the abnormal fibrinogen. This is consistent with, if not predicted from, the functional defect, for it is generally accepted that cleavage of fibrinopeptide B is not essential for fibrinogen coagulation (3, 31, 36) .
The results in Fig. 2A suggest that the delay in plasma coagulation can be abolished at increased thrombin concentrations. Consistent with these data is the observation that the kinetics of fibrinopeptide B release are indistinguishable from normal at thrombin concentrations >3 u/ml. Thus, the functional defect is corrected in vitro by relatively high thrombin concentrations, and this characteristic may contribute to the unremarkable case history of the index patient.
Experiments to assess the initial rates of fibrin monomer polymerization revealed no difference between the abnormal and control fibrinogen. However, the structure of the abnormal fibrin polymer may well be different from normal, as evidenced by the divergence in solution turbidity at later time points (Fig. 4) Congenital hypodysfibrinogenemia has been described in six families in addition to that reported here (44) (45) (46) (47) (48) (49) . Fibrinogen Bethesda II (44) , which manifests a slight delay in total fibrinopeptide release, also exhibits a major delay in fibrin monomer polymerization and is therefore dissimilar to fibrinogen Baltimore II. The remaining proteins (45) (46) (47) (48) (49) are delayed only in the polymerization phase of coagulation. Thus, fibrinogen Baltimore II is readily distinguished from the other hypodysfibrinogens on the basis of its functional defect, a delay in fibrinopeptide B release.
The steady-state plasma fibrinogen concentration is essentially a function of its synthetic rate and rate of plasma clearance. We found the catabolic rate for fibrinogen Baltimore II to be within normal limits and conclude that the hypofibrinogenemia results from a synthetic rate about one-third of normal (Table 3) . Plasma fibrinogen survival has been studied in four of the six previously described hypodysfibrinogenemias. Two of these, fibrinogens Bethesda III (45) and Philadelphia (46), were markedly hypercatabolized. A third, fibrinogen Bethesda 11 (44) , was reported to have a slightly increased fractional catabolic rate, a somewhat shortened plasma half-life (70-72 hr), and a normal synthetic rate. Thus, the etiology of the subnormal fibrinogen levels in these three cases differs from that of fibrinogen Baltimore II. In the fourth instance (49), subnormal plasma fibrinogen concentrations were not due to hypercatabolism and thus resulted from a decreased synthetic rate. However, the functional and solubility characteristics of this protein readily distinguish it from the present one.
On the basis of the foregoing we conclude that fibrinogen Baltimore II is unique among the dysfibrinogens and suggest that a similarly unique structural defect is present in this protein.
